In an Exciting Turn of Events, N4 Pharma Discloses Successful Approval of All General Meeting Resolutions

In a significant move that underscores its burgeoning profile within the biotech sector, N4 Pharma PLC unveiled with considerable satisfaction that all proposed resolutions tabled at the General Meeting were duly approved. The full details of the resolutions are accessible on the Company’s official website for the public’s perusal. Moving on the momentum of this outcome, the groundbreaking biotech firm announced its decision to issue an enormous tranche of 294,719,650 shares, aptly labeled the ‘Second Issue Shares,’ along with the promised Fundraise Warrants and Broker Warrants. This revelation follows their prior announcement on April 1, 2025. The admittance of these Second Issue Shares for AIM trading on the London Stock Exchange is pending, with expectations that trading will kick off on or around April 23, 2025. This latest issuance will scale up the aggregate number of Ordinary Shares in the company to a staggering 832,280,349. With no shares retained in the treasury, the total number of voting rights following this issuance will be identical. Shareholders can now consider these Total Voting Rights as their calculation baseline if they are asked to declare their interests or any alterations therein, as per the Company’s principles and the FCA’s Disclosure and Transparency Rules. N4 Pharma, the renowned pre-clinical biotech outfit, is devoted to improving and enabling advanced therapies for cancer and other challenging diseases via its proprietary gene delivery system, Nuvec®. This unwavering dedication is buttressed by the promising potential of RNA therapeutics, which are poised to revolutionise disease treatments. N4 Pharma is steadily building a robust preclinical dataset while paving the way towards valuable licensing agreements for the Nuvec® platform.